Lynn Seely, Myovant CEO

My­ovant’s re­l­u­golix wins a piv­otal prostate can­cer show­down with an old stan­dard — com­ing down to the wire on ap­provals

My­ovant $MY­OV has round­ed the fi­nal turn in its de­vel­op­ment race to get re­l­u­golix down to the reg­u­la­to­ry wire at the FDA. And the biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA